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Background:  Although  we  have  previously  reported  that  the  presence  of  paroxysmal  atrial  ﬁbrillation
(AF)  is an  independent  risk  factor  for rehospitalization  in patients  with  congestive  heart  failure  (CHF)  in a
population  from  1996  to  2002,  the  impact  of  AF  conﬁguration  as  a  risk  factor  in a more  recent  population
remains  to be  clariﬁed.
Methods and  results:  319  patients  with  CHF  admitted  to  our  institute  in  2006–2007  were  retrospectively
evaluated.  The  patients  were  divided  into  3 groups  in  accordance  with  their  basic  cardiac  rhythm,  i.e.trial ﬁbrillation
eart failure
isk factors
sinus rhythm  (n  = 210),  chronic  AF  (n  =  68),  and  paroxysmal  AF  (n = 41).  During  the  follow-up  period  of
19  ±  17  months,  there  was  no signiﬁcant  difference  in  mortality  or rehospitalization  events  among  the  3
groups (p  = 0.542).  In the  multivariate  analysis,  no administration  of  -blockers  was  the  only  independent
risk  factor  for  rehospitalization  due  to  CHF  exacerbation.
Conclusions:  The  clinical  impact  of  AF  conﬁguration  as a risk  factor  of  rehospitalization  due  to  CHF
exacerbation  was  considered  to be decreased  in recent  years.
© 2012  Japanese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.ntroduction
Atrial ﬁbrillation (AF) is one of the most common types of
rrhythmia in clinical practice and it is considered to be responsible
or substantial morbidity and mortality in some types of diseases
1–4]. Theoretically, the rapid ventricular rate during AF reduces
he length of the diastolic phase and it results in a decrease in
emodynamic ventricular ﬁlling. The lack of atrial contraction also
ontributes to a reduction in the ventricular ﬁlling at the end of
he diastolic phase. It has been reported that these changes reduce
ardiac output by 20–40% depending on the basic situation [5–7].
eta-analyses of several mega-trials, including SOLVD, CHARM,
tc., have demonstrated the contribution of AF rhythm to a worse
rognosis in patients with heart failure (HF) in comparison with
inus rhythm [8,9]. However, the more recent JCARE-CARD and AF-
HF studies have documented no signiﬁcant difference between
atients with and without AF, even in cases of HF when appro-
riate rate control and anticoagulation therapies were performed
∗ Corresponding author at: Department of Cardio-Angiology, Kitasato University
chool of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0374,
apan. Tel.: +81 42 778 8111; fax: +81 42 778 8441.
E-mail address: masamim@med.kitasato-u.ac.jp (M.  Murakami).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
oi:10.1016/j.jjcc.2012.01.020[10–13].  Although the reason for this discrepancy is unclear, sev-
eral improvements in the modality of HF therapy in recent years,
such as brain-natriuretic peptide (BNP)-guided therapy, -blocker
therapy, and renin–angiotensin system (RAS) suppression ther-
apy may  have reduced the impact of AF on the prognoses for
HF patients [14]. Our institute has also reported similar ﬁndings.
When retrospective observations of HF patients were performed
in a patient population from 1996 to 1999, the rehospitalization
event rate was  higher in patients with AF than those without AF
[15], but the difference became insigniﬁcant in a patient popula-
tion from 1996 to 2002 [14]. Interestingly, the latter study exhibited
a higher rehospitalization event rate in patients with paroxysmal
AF than chronic AF or sinus rhythm. The results of the latter study
might suggest that the impact of AF on HF patients depends not
on the presence of AF but on a change in basic rhythm [14], but
this concept was  not conﬁrmed in the sub-analysis of the AF-CHF
study. Therefore, we  planned to re-evaluate the impact of AF on
HF patients in a more recent population in our institute reﬂect-
ing more recent therapeutic modality of HF therapy. In the present
study, the rehospitalization events of HF patients were evaluated
in a recent population. Clinical parameters were retrospectively
compared between the patients with and without rehospitalization
events to clarify the clinical factors which determine the prognoses
of HF patients.
vier Ltd. All rights reserved.
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atient population
The study population consisted of 319 consecutive patients
ith exacerbated HF diagnosed with congestive HF (CHF) for
he ﬁrst time, according to the Framingham criteria, admitted to
itasato University Hospital from January 2006 to December 2007.
atients with permanent pacemaker implantation and patients
ho died on their ﬁrst admission were excluded. The mean age
as 70 ± 14 years and 116 were female. The clinical characteris-
ics of the patients are summarized in Table 1. Clinical parameters
ere basically analyzed at the time of hospital discharge as the
atient baseline characteristics for HF. The mean heart rate was cal-
ulated from the Holter electrocardiogram (ECG) recording or the
rend data of consecutive ECG monitoring during admission. Find-
ngs on ultrasonic cardiography were recorded by trans-thoracic
chocardiogram (Aplio, Toshiba Co. Ltd., Tokyo, Japan). The dimen-
ion of each chamber was measured in the left parasternum
iew, and the ejection fraction was calculated using the mod-
ﬁed Simpson method. Structural heart disease was  diagnosed
y routine echocardiography and/or cardiac catheterization. The
istory of cardiac surgery included any type of surgical proce-
ure, such as open chest or open heart surgery, and coronary
nterventions. Patients who underwent catheter ablation for AF
uch as pulmonary vein isolation were not included in the study
opulation. All studies were performed with the approval of the
able 1
linical characteristics and comparison of patients with and without rehospitalization.
Total Rehospita
Age 69.7 ± 14.0 73.1 ± 12.
Male, no.(%) 203(63.6) 64(64.7) 
Underlying cardiovascular disease of HF, no.(%)
IHD 145(45.5) 50(50.5)
CM 39(12.2) 8(8.1) 
VHD 59(18.5) 24(24.2) 
HHD  23(7.2) 4(4.0) 
Other  53(16.6) 13(13.2) 
Complicating disorder, no.(%)
HT 187(58.6) 65(65.7) 
DM 117(36.7) 35(35.4) 
Old  CI 30(9.4) 8(8.1) 
On  admission
NYHA(II:III:IV) 55:162:102 12:53:34 
On  discharge
Heart rate, bpm 75 ± 15 76 ± 18 
LAD,  mm 42.7 ± 11.4 46.1 ± 16.
LVDd, mm 53.3 ± 10.3 53.6 ± 11.
LVEF,  % 47.3 ± 14.4 44.6 ± 14.
CTR,  % 54.8 ± 7.6 56.4 ± 7.6
BNP, pg/ml 137.3 ± 160.3 170.6 ± 16
ECG rhythm group, no.(%)
SR 210(65.8) 61(61.6) 
PAF  41(12.9) 15(15.2) 
CAF  68(21.3) 23(23.2) 
Cardiac surgery, no.(%) 145(45.5) 47(47.5)
Medication use, no.(%)
Statin 126(39.5) 32(32.3) 
ACE  inhibitors/ARB 288(90.3) 93(93.9) 
-Blocker 188(58.9) 49(49.5) 
Spironolactone 93(29.2) 27(27.3) 
Digoxin 88(27.6) 26(26.3) 
Amiodarone 15(4.7) 6(6.1) 
Warfarin 123(38.6) 31(31.3) 
TTR  (%) 61.7 ± 9.7 61.5 ± 10.
F, heart failure; IHD, ischemic heart disease; CM,  cardiomyopathy; VHD, valvular heart d
I,  cerebral infarction; NYHA, New York Heart Association; LAD, left atrial dimension; LVD
TR,  cardiothoracic ratio; BNP, brain natriuretic peptide; ECG, electrocardiogram; SR, sin
ngiotensin-converting enzyme; ARB, angiotensin-receptor blocker; TTR, time in therape
* p < 0.05 between the patients with rehospitalization.
† p < 0.01 between the patients without rehospitalization.rdiology 60 (2012) 36–41 37
Clinical Studies and Ethics Committee of Kitasato University Hos-
pital.
Evaluation of the factors determining rehospitalization
Rehospitalization events due to exacerbation of CHF were ret-
rospectively evaluated from the time of hospital discharge until
December 2010. In the present study, we picked up the rehospi-
talization event due to exacerbation of CHF and the other causes
of rehospitalization events, that include cardiopulmonary arrest,
ventricular tachycardia/ﬁbrillation, acute myocardial infarction,
cerebral infarction, hemorrhagic episode, etc., were excluded. The
event was counted when the main reason for the second hos-
pitalization was  the exacerbation of CHF. After the retrospective
observation, the patients were divided into two  groups with and
without rehospitalization events. Clinical parameters were com-
pared between the two  groups by uni- and multi-variate analyses
to clarify the factors determining rehospitalization events.
All patients were divided into three groups in accordance
with the basic cardiac rhythm during their ﬁrst hospitalization as
follows: (1) a sinus rhythm (SR) group who exhibited no docu-
mentation of AF during their hospitalization (n = 210); (2) a chronic
AF (CAF) group who exhibited continuous AF and were diagnosed
as CAF during their hospitalization (n = 68); and (3) a paroxysmal
AF (PAF) group who  exhibited spontaneous changes between SR
and AF and were diagnosed as PAF during their hospitalization
(n = 41) [16]. The therapeutic strategy for AF in individual patients,
lization(+) Rehospitalization(−) p-Value
5 68.2 ± 14.4 0.0059†
139(63.2) 0.8014
95(43.2) 0.2243
31(14.1) 0.1295
35(15.9) 0.0761
19(8.6) 0.1420
40(18.2) 0.2622
122(55.5) 0.0870
82(37.3) 0.7421
22(10.0) 0.5869
43:109:68 0.2660
74 ± 13 0.7412
0 41.4 ± 8.4 0.0106*
5 53.1 ± 0.8 0.8819
4 48.5 ± 14.3 0.0668
 54.1 ± 7.4 0.0080†
.2 121.0 ± 11.3 0.0034†
149(67.7) 0.2870
26(11.8) 0.4105
45(20.5) 0.5752
98(44.6) 0.6269
94(42.7) 0.0786
195(88.6) 0.1390
139(63.2) 0.0215*
66(30.0) 0.6200
62(28.2) 0.7429
9(4.1) 0.4420
92(41.8) 0.0745
1 61.8 ± 9.7 0.7052
isease; HHD, hypertensive heart disease; HT, hypertension; DM,  diabetes mellitus;
d, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction;
us rhythm; PAF, paroxysmal atrial ﬁbrillation; CAF, chronic atrial ﬁbrillation; ACE,
utic range.
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ncluding rhythm control, rate control, and anticoagulation ther-
py, was decided by plural experienced cardiologists. The clinical
arameters, including rehospitalization and total death events,
ere compared among these 3 groups. In this case, rehospitaliza-
ion was due to exacerbation of CHF as above, and total death was
eath due to all causes. To evaluate the effect of cardiac rhythm, in
ddition to the comparison between the three groups were com-
ared the presence of any type of AF.
tatistical analysis
Continuous data are expressed as mean ± SD. Patient charac-
eristics were compared using the chi-squared test and one-way
nalysis of variance test. The event-free rates among the groups
ere calculated using the Kaplan–Meier method, and differences
mong the groups were deﬁned as a p-value of <0.05 (two-tailed)
or all analyses. The Cox proportional hazards model was applied to
valuate differences in the occurrence of rehospitalization for CHF
xacerbation among the groups after taking into account the effect
f several potential confounders using the statistical software JMP
JMP 7.0, SAS Inc. Tokyo, Japan).
esults
ncidence and determinants of rehospitalization events
During the retrospective observation period of 12–61 months
19 ± 17 months), rehospitalization events were recorded in 99/319
atients. Table 1 shows the clinical characteristics of the patients
ith and without rehospitalization events. Among the parame-
ers, the age was older, left atrial dimension (LAD) was  larger,
ardiothoracic ratio (CTR) was larger, and BNP level was higher in
atients with rehospitalization events than those without events.
he incidence of -blocker prescription was lower in patients with
ehospitalization events than those without events.
Table 2 exhibits the result of uni- and multivariate analyses of
he clinical parameters as risk factors for rehospitalization events.
he univariate analysis shows that signiﬁcant risk factors for the
ehospitalization events were higher age, higher minimum level of
NP, larger CTR, larger LAD, and no administration of -blockers. In
he multivariate analysis, no-administration of -blockers was  the
able 2
ni- and multi-variate analyses of the risk factors for the rehospitalization.
Univariate 
p-Value 
Age 0.0059 
Gender(male) 0.8014 
Presence of PAF 0.4105 
Presence of CAF 0.5752 
Presence of any type of AF 0.2870 
Valvular heart disease 0.0761 
NYHA 0.1459 
History of cardiac surgery 0.6269 
HR,  bpm 0.7412 
Lowest BNP, pg/dl 0.0034 
CTR,  % 0.0080 
LVEF,  % 0.0668 
LAD,  mm 0.0106 
Non-administration of statin 0.0736 
Non-administration of ACEI/ARB 0.1665 
Non-administration of -blocker 0.0199 
Non-administration of digoxin 0.7055 
5%CI, 95% conﬁdence interval; PAF, paroxysmal atrial ﬁbrillation; CAF, chronic atrial ﬁb
NP,  brain natriuretic peptide; CTR, cardiothoracic ratio; LVEF, left ventricular ejection fr
RB,  angiotensin-receptor blocker.
* p < 0.05.rdiology 60 (2012) 36–41
only signiﬁcant factor indicating that this is an independent risk
factor for rehospitalization events.
Comparison of patients with different basic cardiac rhythms
Table 3 shows a comparison of the 3 sub-groups with differ-
ent basic cardiac rhythms, i.e. SR, PAF, and CAF. In comparison
with the SR group, the PAF group exhibited higher age, higher
incidence of digoxin administration, and lower incidence of statin
administration. In contrast, the CAF group exhibited higher preva-
lence of valvular heart disease, larger CTR, higher BNP level, larger
LAD, higher incidence of digoxin administration, and lower inci-
dence of statin administration in comparison with the SR group.
The PAF group showed smaller LAD, smaller CTR, lower BNP level,
and higher incidence of amidarone administration in comparison
with the CAF group. The incidence of death or rehospitalization
events did not show any signiﬁcant differences among the 3 groups.
Fig. 1 shows the Kaplan–Meier event-free curves of each group for
rehospitalization and total death events. There was no signiﬁcant
difference in rehospitalization events among the 3 groups (Panel A).
Although the SR group tended to exhibit better prognosis in terms
of total deaths (Panel B), there was  no signiﬁcant difference among
the 3 groups.
Discussion
Relationship between rehospitalization due to CHF exacerbation
and AF burden
It has been considered that AF would be a risk factor for exacer-
bation of CHF [8,9]. Shortening of the diastolic phase and a lack
of atrial contraction, which can both be observed in AF, reduce
ventricular ﬁlling and will theoretically reduce cardiac output
[5–7]. These hemodynamic changes may  practically exacerbate the
CHF in clinical patients, and earlier reports have documented the
contribution of AF to worsening prognoses in patients with CHF
[8,9]. However, more recent studies have demonstrated no sig-
niﬁcant difference in prognoses between CHF patients with and
without AF when appropriate rate control and anticoagulation
therapies were given [10–12]. This difference is considered to be
explained by recent changes in the therapeutic modality for CHF
patients. The use of -blockers and/or RAS suppressing medicines
Multivariate
Odds ratio 95%CI p-Value
0.148 −0.062 to 0.003 0.0550
1.461 −0.240 to 0.618 0.3841
0.004 . . . 0.6958
0.001 . . . 0.7131
0.001 . . . 0.7072
0.910 −0.482 to 0.397 0.8339
0.003 . . . to 0.321 0.8636
0.590 −0.611 to 0.075 0.1296
1.276 −0.019 to 0.027 0.7463
0.255 −0.004 to 0.001 0.2643
0.381 −0.079 to 0.045 0.5874
7.228 0.003 to 0.057 0.0530
0.142 −0.081 to 0.004 0.0796
0.651 −0.576 to 0.139 0.2374
1.796 −0.350 to 1.079 0.4077
0.614 −0.601 to 0.112 0.0178*
1.129 −0.342 to 0.445 0.7635
rillation; AF, atrial ﬁbrillation; NYHA, New York Heart Association; HR, heart rate;
action; LAD, left atrial dimension; ACEI, angiotensin-converting enzyme inhibitor;
M. Murakami et al. / Journal of Cardiology 60 (2012) 36–41 39
Table  3
Clinical characteristics of the SR, PAF, and CAF groups.
SR group (n = 210) PAF group (n = 41) CAF group (n = 68)
Age 68.2 ± 14.4 73.5 ± 14.1* 72.3 ± 11.8
Male,  no.(%) 137(65.2) 24(58.5) 44(64.7)
Underlying cardiovascular disease of HF, no.(%)
IHD 110(52.4) 15(36.6) 20(29.4)†
CM 31(14.7) 4(9.8) 4(5.9)
VHD  30(14.3) 7(17.1) 22(32.4)†
HHD 19(9.1) 4(9.8) 0(0)*,§
Other 20(9.5) 11(26.7)† 22(32.3)†
Complicating disorder, no.(%)
HT 128(61.0) 23(56.1) 36(52.9)
DM 90(42.9) 11(26.8) 16(23.5)†
Old CI 20(9.5) 3(7.3) 7(10.3)
On  admission
NYHA, II:III:IV 40:100:70 9:20:12 6:42:20
On  discharge
Heart rate, bpm 73 ± 14 73 ± 12 79 ± 17*
LAD, mm 40.1 ± 7.2 40.5 ± 7.7 52.7 ± 17.4† ,§
LVDd, mm 53.8 ± 10.4 51.6 ± 9.0 52.5 ± 10.8
LVEF,  % 45.5 ± 14.9 50.5 ± 11.5 51.4 ± 13.4†
CTR, % 53.5 ± 6.6 53.0 ± 5.4 60.0 ± 9.1† ,§
BNP, pg/ml 129.6 ± 166.8 109.9 ± 104.5 174.6 ± 164.1† ,§
Medication use, no.(%)
Statin 99(47.1) 10(24.4)† 17(25.0)†
ACE inhibitors/ARB 192(91.4) 35(85.4) 61(89.7)
-Blocker 129(61.4) 23(56.1) 36(52.9)
Spironolactone 59(28.1) 11(26.8) 23(33.8)
Digoxin 35(16.7) 15(36.6)* 38(55.9)†
Amiodarone 10(4.8) 4(9.8) 1(1.5)‡
Warfarin 53(25.2) 21(51.2)† 49(72.1)† ,‡
TTR (%) 61.1 ± 10.3 60.1 ± 8.7 63.1 ± 9.6
Death,  no.(%)
Total death 18(8.6) 5(12.2) 9(13.2)
CHF  8 1 2
VT/VF 3 2 3
Other  7 2 4
Rehospitalization due to CHF 61(29.1) 15(36.6) 23(33.8)
SR, sinus rhythm; PAF, paroxysmal atrial ﬁbrillation; CAF, chronic atrial ﬁbrillation; HF, heart failure; IHD, ischemic heart disease; CM,  cardiomyopathy; VHD, valvular heart
disease; HHD, hypertensive heart disease; HT, hypertension; DM,  diabetes mellitus; CI, cerebral infarction; NYHA, New York Heart Association; LAD, left atrial dimension;
LVDd,  left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; CTR, cardiothoracic ratio; BNP, brain natriuretic peptide; ACE, angiotensin-converting
enzyme; ARB, angiotensin-receptor blocker; TTR, time in therapeutic range; CHF, congestive heart failure; VT, ventricular tachycardia; VF, ventricular ﬁbrillation.
* p < 0.05 vs. SR group.
† p < 0.01 vs. SR group.
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§ p < 0.01 vs. PAF group.
angiotensin-converting enzyme (ACE) inhibitors or angiotensin
eceptor blockers (ARBs)] has improved the prognoses of CHF
atients [17–20],  while the use of various new biomarkers, such as
NP, has enabled stricter control of CHF in clinical practice [21,22].
hese improvements may  have reduced the contribution of AF to
orse prognoses, and as a result, the difference between patients
ith and without AF may  have become insigniﬁcant in recent years.
n contrast, our previous report documented a unique ﬁnding. The
esult was that no signiﬁcant difference was observed in rehos-
italization and total death events between SR and CAF patients
n the study population of CHF patients in 1996–2002, while only
AF patients with CHF exhibited worse prognoses than the oth-
rs [14]. Because it was a retrospective observation of CHF patients
nder continuous CHF therapies, the result is understandable when
e consider that not the presence of AF but rather a change in
asic rhythm is a risk for CHF exacerbation. However, as this phe-
omenon could not be conﬁrmed by other reports, we  re-evaluated
he same concept in a more recent population in this study. The
esult was that, similar to other recent reports, no signiﬁcant dif-
erence could be found among the patients with SR, PAF, and CAF in CHF population. The precise mechanism of this change is unclear
ut may  be explained by changes in adherence to the therapeutic
uidelines for CHF therapies that have occurred in recent years,
t least at our institute. At the time of the previous report, i.e.1996–2002, the latest CHF therapies such as BNP-guided therapy
and use of -blockers, ACE inhibitors, or ARBs, were already used,
but adherence may  have been limited. When we compared the
clinical characteristics of the study populations in 2 different time
periods at our institute, because the method of patient selection
and the analyzed parameters were different between the 2 studies,
the comparison was  incomplete but has revealed one possible rea-
son. Although the total population and subgroups with SR or CAF
exhibited increase in the use of -blockers, ACE inhibitors, or ARBs,
the subgroup with PAF exhibited differences only in New York
Heart Association class populations and BNP levels on discharge.
At least in PAF subgroups, more strict observance of BNP-guided
therapy in the more recent CHF population might have decreased
the impact of PAF on the worse prognosis in CHF patients. However
this lower BNP level might possibly result from better left ventric-
ular ejection fraction in the more recent population. So that the
interpretation should be concluded carefully, but there was  no cor-
relation between BNP level and left ventricular ejection fraction at
least in this population [14].Risk factors for rehospitalization due to CHF exacerbation
The prediction of CHF exacerbation is an important issue in clini-
cal management of CHF patients. As discussed above, AF prevalence
40 M. Murakami et al. / Journal of Ca
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Fig. 1. Kaplan–Meier event-free curves for rehospitalization and total death events
in  groups with different cardiac rhythms. This ﬁgure shows Kaplan–Meier event-free
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here was  no signiﬁcant difference among the 3 groups for these events. SR, sinus
hythm; PAF, paroxysmal atrial ﬁbrillation; CAF, chronic atrial ﬁbrillation.
as considered to be a risk for CHF worsening in earlier reports
1–4,8,9], but its impact should be considered as small or insignif-
cant by referring to more recent reports [10–13].  Referring to our
wn data, not CAF, but rather PAF, may  be a risk for CHF exacer-
ation [14], although its importance has decreased following the
ntroduction of therapeutic procedures with higher adherence to
he recommended guidelines.
Kubler et al. reported that lowering the BNP level by less than
0% during hospitalization would be a predictor for rehospitaliza-
ion [23]. However, in our study population, this parameter was
ot signiﬁcant for prediction of rehospitalization (p = 0.307, data
ot shown). Because we employ BNP < 200 pg/ml as one of the
riteria for hospital discharge in our institute, we  also evaluated
NP > 200 pg/ml as a predictor for clinical events, but it was  not
igniﬁcant either. BNP is a good marker to evaluate the response
f the patient’s heart to CHF treatment, but the BNP level at hos-
ital discharge may  not reach its lowest level because the term of
ospitalization is limited. Additionally, BNP may  reﬂect the condi-
ion of not only the left ventricle, but also the right ventricle or the
tria. Therefore, BNP at the time of hospital discharge may  not be a
imple independent predictor of future events.
Other reports demonstrated that no use of -blockers, ACE
nhibitors, or ARBs was a risk factor for rehospitalization
17,18,24–26]. Similar to these reports, we found that no use of -
lockers was the only independent predictor for rehospitalization
vents in the present study, but no use of ACE inhibitors or ARBs
as not. The precise mechanism for the latter result is unclear, but it
as probably due to the limited population of patients not receivingrdiology 60 (2012) 36–41
ACE inhibitors or ARBs (9.7%) in this study. Referring to the guide-
lines for CHF treatment, the use of -blockers or RAS-suppressing
medicines should be important and probably essential to prevent
future events.
Limitations
There are a few limitations in this study. First, the study was
carried out at a single center in both a retrospective and nonran-
domized fashion. The acquired data may  be biased depending on
the clinical status and judgment of each patient. Second, there were
some differences in clinical backgrounds in the 3 subgroups with
different cardiac rhythms. The differences may  have inﬂuenced the
results of comparisons among the 3 groups even though the results
showed no difference in prognoses. Third, because the observa-
tion was set retrospectively, therapies were not randomized, there
are some missing data which could be useful to understand the
patients’ conditions, such as catecholamine level, so that the dif-
ferences in therapies resulted in some bias. Finally, although the
detection of AF itself was  carefully performed by continuous mon-
itoring, asymptomatic AF cannot be ruled out completely.
Conclusions
At least in the recent population, the presence or absence of
AF did not affect the rehospitalization events due to CHF exacer-
bation in patients with history of CHF. The clinical impact of AF
conﬁguration as a risk factor of rehospitalization due to CHF exac-
erbation was considered to be decreased in recent years. This may
be due to improved adherence, especially the usage of -blockers,
to recommended therapies for CHF patients.
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